Clinical Trials

Our animation explores the unique challenges a "no-deal" Brexit poses for the drug development and advanced therapy sectors.

Orphan drugs for rare diseases represent a significant unmet medical need for pharma, but commercialication can be tricky...

Artificial Intelligence and other innovative technologies have the potential to disrupt every stage of the clinical trial process.

With cell and gene therapies being all the rage, we take a peek at some of the advanced therapies coming down the pipe.

A key focus of Andrew McLachlan’s career is understanding the impact of aging on drug disposition and response to medicines.

No-deal Brexit poses unique challenges for the development and advanced therapy sectors, not least tight timelines and a limited ability to stockpile.

What does the controversial genome editing work of Jiankui He mean for biomedical research?

Only 50 percent of clinical trial results in Europe are reported, but big pharma shares far less than half the blame.

The PRGLAC Task Force hopes to change the landscape for research on pregnant and lactating women.

Including pregnant women in research isn’t as difficult as some might think…